Pediatrix Medical Group (FRA:PDC) Cash Conversion Cycle: 34.68 (As of Mar. 2026)


FRA:PDC Pediatrix Medical Group Inc FRA:PDC
61 GF Score
Price €21.00
GF Value €11.17
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Pediatrix Medical Group Cash Conversion Cycle?

Pediatrix Medical Group FRA:PDC -0.94% 61 Cash Conversion Cycle is 34.68 as of Mar. 2026. GuruFocus rates FRA:PDC with a GF Score™ of 61/100 and a GF Value™ of €11.17 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Pediatrix Medical Group's Days Sales Outstanding for the three months ended in Mar. 2026 was 43.26.
Pediatrix Medical Group's Days Inventory for the three months ended in Mar. 2026 was 0.
Pediatrix Medical Group's Days Payable for the three months ended in Mar. 2026 was 8.58.
Therefore, Pediatrix Medical Group's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2026 was 34.68.


Pediatrix Medical Group  (FRA:PDC) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Pediatrix Medical Group Cash Conversion Cycle Related Terms


Pediatrix Medical Group Cash Conversion Cycle Historical Data

* Premium members only.

The historical data trend for Pediatrix Medical Group's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pediatrix Medical Group Cash Conversion Cycle Chart

Pediatrix Medical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 38.24 45.62 45.05 37.95 38.16

Pediatrix Medical Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.05 36.62 33.37 33.13 34.68

FRA:PDC vs SGRY, ADUS, SNDA: Cash Conversion Cycle Comparison

For the Medical Care Facilities subindustry, Pediatrix Medical Group's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pediatrix Medical Group Cash Conversion Cycle vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Pediatrix Medical Group's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Pediatrix Medical Group's Cash Conversion Cycle falls into.


FRA:PDC
61GF Score
Pediatrix Medical Group Inc FRA:PDC
Cash Conversion Cycle is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pediatrix Medical Group Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Pediatrix Medical Group's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=49.62+0-11.46
=38.16

Pediatrix Medical Group's Cash Conversion Cycle for the quarter that ended in Mar. 2026 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=43.26+0-8.58
=34.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash Conversion Cycle →
What does a Cash Conversion Cycle of 34.68 mean?
Pediatrix Medical Group (FRA:PDC) has a Cash Conversion Cycle of 34.68 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Pediatrix Medical Group and its competitors.
Is Pediatrix Medical Group's Cash Conversion Cycle too high?
Pediatrix Medical Group's current Cash Conversion Cycle is 34.68. The Healthcare Providers & Services industry median Cash Conversion Cycle is 18.21. Pediatrix Medical Group's value of 34.68 is 90.4% above this industry median. Overall, Pediatrix Medical Group has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pediatrix Medical Group's Cash Conversion Cycle compare to SGRY and ADUS?
Pediatrix Medical Group's Cash Conversion Cycle of 34.68 can be compared against companies in the Healthcare Providers & Services industry. The industry median Cash Conversion Cycle is 18.21. Pediatrix Medical Group's value of 34.68 is 90.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Healthcare Providers & Services company?
The median Cash Conversion Cycle among Healthcare Providers & Services companies is 18.21, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pediatrix Medical Group's current Cash Conversion Cycle of 34.68 is 90.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Pediatrix Medical Group and its competitors. For the Healthcare Providers & Services industry, the median Cash Conversion Cycle is 18.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pediatrix Medical Group's current Cash Conversion Cycle is 34.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pediatrix Medical Group stock overvalued right now?
Based on GuruFocus' analysis, Pediatrix Medical Group (FRA:PDC) is currently considered Significantly Overvalued. The stock's GF Value™ is €11.17, compared to a current price of €21.00 — trading 88% above its estimated fair value. The current Cash Conversion Cycle is 34.68 and 90.4% above the Healthcare Providers & Services industry median of 18.21. Pediatrix Medical Group's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Pediatrix Medical Group (FRA:PDC), the current Cash Conversion Cycle is 34.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pediatrix Medical Group (FRA:PDC) Overvalued in 2026?

Based on GuruFocus' analysis, Pediatrix Medical Group stock appears to be overvalued. The current stock price of €21.00 is trading 88% above its estimated GF Value™ of €11.17. GuruFocus considers Pediatrix Medical Group to be Significantly Overvalued.

Key valuation signals for FRA:PDC:

  • Cash Conversion Cycle: 34.68
  • GF Value™: €11.17 vs. price of €21.00 (88% above fair value)
  • GF Score™: 61/100 with 7 warning signs
  • Industry Position: 90.4% above the Healthcare Providers & Services median

No single metric tells the full story. See the FRA:PDC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pediatrix Medical Group Business Description

Other Exchanges MD:USA
Address 1301 Concord Terrace, Sunrise, FL, USA, 33323
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
61GF Score

Get the complete analysis for FRA:PDC

Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.00
Price
€11.17
GF Value